Assessment of minimal residual disease in acute myeloid leukemia
- 1 November 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Oncology
- Vol. 22 (6), 656-663
- https://doi.org/10.1097/cco.0b013e32833ed831
Abstract
Purpose of review The last 15 years have witnessed significant improvements in technologies to detect minimal residual disease (MRD) in acute myeloid leukemia (AML). We review recent studies highlighting the potential for novel and standardized assays to provide independent prognostic information and develop more personalized treatment approaches. Recent findings Progress includes establishment of optimized real-time quantitative PCR (RQ-PCR) assays for WT1 (commonly overexpressed and a putative therapeutic target) and mutant NPM1 genes. Moreover, sequential MRD monitoring using an internationally standardized PML-RARA RQ-PCR assay has been successfully used to guide molecularly targeted therapy in acute promyelocytic leukemia (APL). There have also been significant advances in multiparameter flow cytometry (MFC) to detect MRD, with introduction of 6-10 color technology and improved understanding of the immunophenotype of leukemic stem cells. Summary Sensitive MRD detection using MFC and/or RQ-PCR has become feasible in virtually all AML patients. MRD monitoring is now considered a standard of care in APL. Recent studies provide a strong rationale for prospective trials investigating the merits of extending MRD detection to alter therapy and potentially improve outcome in other AML subtypes.Keywords
This publication has 42 references indexed in Scilit:
- Molecular genetics in acute myeloid leukemiaCurrent Opinion in Oncology, 2010
- Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trialsBlood, 2010
- Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatmentPublished by American Society of Hematology ,2010
- AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic featuresBlood, 2009
- Flow cytometry and the stability of phycoerythrin‐tandem dye conjugatesCytometry Part A, 2009
- Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem CellsCell Stem Cell, 2009
- Advances in complex multiparameter flow cytometry technology: Applications in stem cell researchCytometry Part B: Clinical Cytometry, 2009
- Independent prognostic factors for AML outcomeHematology, 2009
- Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS studyLeukemia, 2008
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003